# Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

> **NCT01684878** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 208 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Gemcitabine (Chemotherapy)
- **DRUG:** Paclitaxel (Chemotherapy)
- **DRUG:** Pertuzumab
- **DRUG:** Placebo
- **DRUG:** Topotecan (Chemotherapy)

## Key facts

- **NCT ID:** NCT01684878
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-22
- **Primary completion:** 2015-01-30
- **Final completion:** 2016-04-28
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01684878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01684878, "Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01684878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*